In patients with well-characterized AML phenotypes such as APL, CBF, and NPM1, follow-up testing is recommended every 3 months using BM sampling in the first 2 years after therapy completion, or every 4–6 weeks using PB [18]. The gene discussed is NPM1; the disease is acute myeloid leukemia.